A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects
Public ClinicalTrials.gov record NCT01171313. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Efficacy, Safety and Pharmacokinetic Study of XP21279 BL2 and Sinemet® in Parkinson's Disease Subjects With Motor Fluctuations
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to assess the efficacy and safety of XP21279/Carbidopa in comparison to Sinemet as well as evaluate the pharmacokinetics (PK) of levodopa after administration of XP21279/Carbidopa and Sinemet and to explore exposure-response relationships in a subset of subjects.
Study identification
- NCT ID
- NCT01171313
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 35 participants
Conditions and interventions
Conditions
Interventions
- XP21279 and carbidopa (experimental) Drug
- Sinemet (comparator) Drug
- Placebo for XP21279 and carbidopa Drug
- Placebo for Sinemet Drug
Drug
Eligibility (public fields only)
- Age range
- 30 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2010 (Type not available)
- Primary completion
- Oct 2011 (Actual)
- Completion
- Dec 2011 (Actual)
- Last update posted
- Feb 18, 2021
2010 – 2011
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| XenoPort Clinical Site | Phoenix | Arizona | 85013 | — |
| XenoPort Clinical Site | Little Rock | Arkansas | 72205 | — |
| XenoPort Clinical Site | Long Beach | California | 90806 | — |
| XenoPort Clinical Site | Sunnyvale | California | 94085 | — |
| XenoPort Clinical Site | Naples | Florida | 34102 | — |
| XenoPort Clinical Site | Tampa | Florida | 33606 | — |
| XenoPort Clinical Site | Kansas City | Kansas | 66160 | — |
| XenoPort Clinical Site | Bingham Farms | Michigan | 48025 | — |
| XenoPort Clinical Site | West Bloomfield | Michigan | 48322-3013 | — |
| XenoPort Clinical Site | New Brunswick | New Jersey | 08901 | — |
| XenoPort Clinical Site | Tulsa | Oklahoma | 74137 | — |
| XenoPort Clinical Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01171313, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 18, 2021 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01171313 live on ClinicalTrials.gov.